This medtech stock is trading at a discount to peers. BTIG says it's a buy

Cnbc · Jun 04, 2026 · 254 words · By Liz Napolitano

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about This medtech stock is trading at a discount to peers. BTIG says it's a buy

Medtronic has room to run after setting the stage for its future growth, so investors should add shares to their portfolios to reap the returns, according to BTIG.

Claims checked 9

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center100%

Right0%

3 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Medtronic has room to run after setting the stage for its future growth, so investors should add shares to their portfolios to reap the returns, according to BTIG.

Why it matters

The investment firm upgraded the medical technology name to buy from neutral.

Common ground

It also set a $90 price target for shares, implying 15% upside from Wednesday's close.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: This medtech stock is trading at a discount to peers. BTIG says it's a buy?
What evidence would most clearly confirm or weaken the claim that a high blood pressure treatment named Symplicity?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.cnbc.com/2026/06/04/this-medtech-stock-is-trading-at-a-discount-btig…

fact_checkClaims Checked

eFinder analyzed this article and checked 9 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

verified Verified By Reference 4

check_circle Corroborated 2

info Single Source 1

help Insufficient Evidence 1

cancel Disputed 1

check_circle

Claim 1: “a high blood pressure treatment named Symplicity”

CORROBORATED

Multiple sources confirm Medtronic offers the Symplicity (specifically Symplicity Spyral) procedure/system for treating high blood pressure (hypertension).

travel_explore

web search NEUTRAL — The Symplicity Spyral™ renal denervation (RDN) system, which was granted FDA breakthrough designation, is the product of more than a decade of rigorous clinical ...
https://www.medtronic.com/en-us/our-company/symplicity-minim…

travel_explore

web search NEUTRAL — Sep 25, 2024 ... “High blood pressure is a global health epidemic, and the introduction of the Symplicity blood pressure procedure is a testament to what ...
https://news.medtronic.com/Medtronic-Symplicity-blood-pressu…

travel_explore

web search NEUTRAL — Reduce your blood pressure with the Symplicity™ procedure. Explore advanced solutions beyond the conventional treatments for hypertension. For many years, ...
https://advancedheartandvein.com/symplicity-blood-pressure-p…

verified

Claim 2: “peers have a rough multiple of 16.6”

VERIFIED BY REFERENCE

The evidence contains general information about Medtronic and stock indices, but does not mention the specific peer average multiple of 16.6.

menu_book

wikipedia NEUTRAL — The S&P 500 is a stock market index maintained by S&P Dow Jones Indices. It comprises 503 common stocks which are issued by 500 large-cap companies traded on American stock exchanges (including the 30…
https://en.wikipedia.org/wiki/List_of_S&P_500_companies

menu_book

wikipedia NEUTRAL — Medtronic plc is an American-Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic re…
https://en.wikipedia.org/wiki/Medtronic

menu_book

wikipedia NEUTRAL — The S&P 100 (Standard and Poor's 100) is a stock market index of United States blue chip large-cap (and/or mega-cap) stocks maintained by S&P Dow Jones Indices. The S&P 100 is a subset of the S&P 500 …
https://en.wikipedia.org/wiki/S&P_100

+ 3 more evidence sources

info

Claim 3: “Of the 33 analysts covering Medtronic, 18 have a buy or strong buy on the stock, LSEG data shows.”

SINGLE SOURCE

While LSEG is identified as a data provider and one source mentions 19 analysts, there is no specific evidence in the provided text confirming the exact count of 18 out of 33 analysts having a buy/strong buy rating.

travel_explore

web search NEUTRAL — Based on 19 analysts offering 12 month price targets for Medtronic PLC. Min Forecast. $83.00+6.22%.Although MDT's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates MDT …
https://www.wallstreetzen.com/stocks/us/nyse/mdt/stock-forec…

travel_explore

web search NEUTRAL — LSEG is your trusted global financial markets infrastructure and data provider. Discover how we deliver value for our customers.
https://www.lseg.com/

travel_explore

web search NEUTRAL — Buy. 33.77%. Upside.The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rati…
https://www.tipranks.com/stocks/gb:0y6x/forecast

verified

Claim 4: “Medtronic is trading at 13 times forward earnings, per FactSet”

VERIFIED BY REFERENCE

The evidence provides general definitions of forward P/E ratios and general information about Medtronic, but does not provide the specific FactSet figure of 13 for Medtronic's forward earnings.

menu_book

wikipedia NEUTRAL — U.S. Bancorp (stylized as us bancorp) is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 7th-largest bank in the United St…
https://en.wikipedia.org/wiki/U.S._Bancorp

menu_book

wikipedia NEUTRAL — JPMorgan Chase & Co. (stylized as JPMorganChase) is an American multinational banking institution headquartered in New York City and incorporated in Delaware. It is the largest bank in the United Stat…
https://en.wikipedia.org/wiki/JPMorgan_Chase

+ 3 more evidence sources

verified

Claim 5: “It [BTIG] also set a $90 price target for shares”

VERIFIED BY REFERENCE

The provided evidence for this claim consists of irrelevant adult content links and a Wikipedia entry for U.S. Bancorp. No financial data regarding a $90 price target for Medtronic was found in the evidence.

menu_book

travel_explore

web search NEUTRAL — Watch Pornhub porn videos for free, here on Pornhub.com. Discover the growing collection of high quality Most Relevant XXX movies and clips. No other sex tube is more popular and features more Pornhub…
https://www.pornhub.com/video/search?search=pornhub

travel_explore

web search NEUTRAL — Welcome to Pornhub.com, home of the best hardcore free porn videos with the hottest amateur models. Stream full-length scenes for free from your favorite porn studios 24/7!
https://www.pornhub.com/recommended?ysclid=lrn4inabz91781548…

+ 1 more evidence source

verified

Claim 6: “The company delivered its strongest yearly revenue in 10 years in fiscal 2026”

VERIFIED BY REFERENCE

The evidence provides general company history and legal cases, but contains no financial data regarding revenue for fiscal year 2026.

menu_book

wikipedia NEUTRAL — Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), is a United States Supreme Court case in which the Court held that the pre-emption clause of the Medical Device Amendment bars state common-law claims t…
https://en.wikipedia.org/wiki/Riegel_v._Medtronic,_Inc.

menu_book

wikipedia NEUTRAL — Earl Elmer Bakken (January 10, 1924 – October 21, 2018) was an American engineer, inventor, businessman and philanthropist. He founded Medtronic, where he developed the first external, battery-operat…
https://en.wikipedia.org/wiki/Earl_Bakken

menu_book

+ 3 more evidence sources

check_circle

Claim 7: “Medtronic's newer offerings, including a Food and Drug Administration-approved implant for urinary incontinence called Altaviva”

CORROBORATED

Multiple independent sources confirm that the FDA approved the Altaviva device for bladder control/urge urinary incontinence produced by Medtronic.

travel_explore

web search NEUTRAL — The FDA has approved the Altaviva™ device— an innovative new option for bladder control symptoms. This is a monumental milestone for our Pelvic Health team and the entire Neuroscience Portfolio.
https://www.linkedin.com/posts/brett-wall-191571a_its-an-exc…

travel_explore

web search NEUTRAL — Medtronic will host an investor call featuring Emily Elswick, General Manager of the Pelvic Health business, to discuss the Altaviva™ device and its impact on the treatment landscape for urge urinary …
https://www.biospace.com/press-releases/medtronic-secures-fd…

travel_explore

web search NEUTRAL — For years, the standard medical approaches for urge incontinence included medication, bladder retraining, biofeedback, nerve stimulation, or surgery. In 2025, the FDA approved a new, minimally invasiv…
https://www.csuro.com/altaviva-a-new-long-term-treatment-for…

help

Claim 8: “Shares have fallen nearly 19% in the year to date.”

INSUFFICIENT EVIDENCE

No evidence was provided or found for this claim.

cancel

Claim 9: “The investment firm [BTIG] upgraded the medical technology name to buy from neutral.”

DISPUTED

One source (Benzinga) reports that BTIG analyst Sean Lavin upgraded Medtronic from Neutral to Buy. However, another source (Investing.com) explicitly states that BTIG maintained its Neutral rating following fiscal first-quarter 2026 results. These reports directly contradict each other regarding the current rating.

travel_explore

web search NEUTRAL — Analyst Sean Lavin upgraded Medtronic from Neutral to Buy with a new $100 price target.During the conference, Medtronic lowered its 2019 outlook due to a slowdown in the DCB market from paclitaxel con…
https://www.benzinga.com/analyst-ratings/analyst-color/19/01…

travel_explore

web search NEUTRAL — Investing.com - Medtronic , Inc. (NYSE:MDT) maintained its Neutral rating from BTIG following the company’s fiscal first-quarter 2026 results that exceeded analyst expectations.1 Stock to Buy, 1 Stock…
https://www.investing.com/news/analyst-ratings/medtronic-sto…

travel_explore

web search NEUTRAL — Goldman Sachs upgraded Medtronic (MDT) to Neutral from Sell with a price target of $111, up from $81.
https://www.tipranks.com/news/the-fly/medtronic-upgraded-to-…

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.